BIOiSIM

We use our AI engine to transform drug discovery. Our discoveries help create better medicines faster. Our AI-enabled discovery portfolio includes wholly-owned and co-developed pipeline assets, and is backed by prominent investors. Atomwise developed a machine-learning-based discovery engine that combines the power of convolutional neural networks with massive chemical libraries to discover new small-molecule medicines. The secret to reinventing drug discovery with AI is people. We are dedicated to developing the best AI platform and using it to transform small molecule drug discovery. We have to tackle the most challenging, seemingly impossible targets and streamline the drug discovery process to give drug developers more shots on goal. Computational efficiency enables screening of trillions of compounds in silico, increasing the likelihood of success. Demonstrated exquisite model accuracy, overcoming the challenge of false positives.

GPT-Rosalind is a purpose-built frontier reasoning model developed by OpenAI to accelerate scientific research across biology, drug discovery, and translational medicine. It is designed specifically for life sciences workflows, where researchers must navigate large volumes of literature, experimental data, and specialized databases to generate and validate new ideas. It combines deep domain understanding in areas such as chemistry, genomics, protein engineering, and disease biology with advanced tool-use capabilities, allowing it to interact with scientific databases, analyze experimental outputs, and support complex, multi-step reasoning tasks. It can assist with evidence synthesis, hypothesis generation, literature review, sequence interpretation, and experimental planning, helping scientists move faster from raw data to actionable insights. GPT-Rosalind transforms complex, time-intensive research processes into more efficient AI-assisted workflows.